Full-Time

Senior Mobile Software Engineer

Posted on 3/21/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Sant Cugat del Vallès, Barcelona, Spain

In Person

Category
Software Engineering (1)
Required Skills
Node.js
iOS/Swift
Android Development
Requirements
  • 7+ years of experience building and maintaining mobile applications (iOS, Android, or both), with deep expertise in at least one platform and strong familiarity with the other
  • Knowledge of Node.js, with experience building backend services for universal/deep link handling in mobile applications
  • Proficient in app store management (Apple App Store and/or Google Play Console), including release processes, app configurations, and compliance
  • Hands-on experience with CI/CD tools and pipelines for mobile app delivery
  • Solid background in iterative development and maintaining live digital products
  • Proven ability to design, implement, and maintain reliable, performant, and scalable solutions
  • Degree in Computer Science or a related field, or equivalent professional experience
  • Passion for clean code, robust architectures, and (automated) testing as an integral part of development
  • Strong focus on accessibility, performance, and systemic solutions
  • Excellent communication skills in English, with the ability to give and receive feedback constructively and mentor others
Responsibilities
  • Support our vision and push even further in the mobile sector to develop at scale and guide the development of our entire efforts on the Android platform
  • Participate in developing universal link handling and associated backend services, using Node.js and modern industry standards
  • Work autonomously in an interdisciplinary team, collaborating with developers, designers, QA, and product owners
  • Bring a fresh perspective and creative approach to the development of our Android products
Desired Qualifications
  • Experience with medical, security, or privacy regulations.
  • Knowledge of the diabetes industry or similar regulated health environments.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI acquisition for $750M in 2026 scales AI-driven digital pathology globally.
  • C4 Therapeutics DAC partnership yields up to $1B in next-gen cancer therapies.
  • CT-388 weight-loss drug targets double-digit share against Novo Nordisk, Eli Lilly.

What critics are saying

  • Swiss franc appreciation erodes 70% international revenue immediately.
  • Avastin, Herceptin patents expire 2028, Amgen biosimilars capture 50% share.
  • Tempus-Epic AI pathology platform steals 30% deals from PathAI by Q3 2026.

What makes Roche unique

  • Pioneered mass production of synthetic vitamin C in 1934 as Redoxon.
  • Acquired Genentech majority stake in 1990, entering biotechnology leadership.
  • Secured PCR technology rights from Cetus in 1991 for diagnostics dominance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE